1. The antagonistic effect of the p-receptor blocking compounds propranolol, Ph QA 33 and INPEA on ouabain-induced cardiac fibrillations in guinea-pigs was compared with their local anaesthetic and p-receptor blocking properties.
,8-blocking agents: propranolol, 1-(isopropylamino)-3-(o-phenoxyphenoxy)-2-propanol, HCI (Ph QA 33) (Hermansen, 1968) , and INPEA. These substances were found suitable for the study because of a decreasing order of local anaesthetic potency. In a preliminary screening test propranolol was three times more active than Ph QA 33, while INPEA is reported to be devoid of local anaesthetic action (Murmann, Saccani-Guelfi & Gamba, 1966) .
Methods
Drugs The following compounds were used: (± )-(isopropylamino)-3-(o-phenoxyphenoxy)-2-propanol hydrochloride. j H20 (Ph QA 33) containing 86.9% free base; (±)-propranolol hydrochloride (I.C.I.) containing 87.7% free base, (±)-2-isopropylamino-l-(p-nitrophenyl) ethanol hydrochloride (INPEA, Selvi & Co., Milano) containing 86.0% free base; (± )-adrenaline bitartrate, (± )-isoprenaline sulphate, ouabain, procaine hydrochloride and tetracaine hydrochloride. The compounds were dissolved in saline at the required concentration. All doses and concentrations mentioned in the text refer to the salts except for adrenaline which is expressed in terms of the base.
Anti-arrhythmic effect
The effect of the compounds on ouabain-induced fibrillations was investigated by a modification of the method of Sekiya & Vaughan Williams (1963) . Male guineapigs weighing from 300 to 650 g were anaesthetized with urethane (1.5 g/kg intraperitoneally) and artificially respired. Ouabain was infused intermittently into the jugular vein by means of an infusion pump connected to a laboratory timer. The concentration of ouabain was 50 ug/ml. and the infusion cycle arranged so that 4 jug was infused during a period of 30 sec followed by an interruption of 1.5 min.
Thus 4 jug ouabain was infused during the 2 min cycle-that is 2 jig/min. The infusion was made intermittent in order to allow accurate recordings of the fibrillatory and lethal dose levels of ouabain. The e.c.g. was obtained with bipolar leads according to Schinzel (1933) .
The dose of ouabain infused was fixed to 2 gg/min and not varied according to the weight of the animals. Thus the doses/kg per min varied from 3.1 to 6.7 ,g of ouabain. A statistical analysis showed, however, that the antifibrillatory and fatal doses were independent of the dose of ouabain infused in pg/kg per min within the dose range mentioned. During the infusion of ouabain the typical changes in heart function-bradycardia, ventricular rhythm, etc.-were observed, but only the minimal dose necessary to cause fibrillations and the fatal dose were recorded. The difference between these two doses was calculated after the experiment and is shown in the sixth column of Table 1 . The compounds to be tested for antifibrillatory effect were injected intravenously immediately after the fibrillations were manifest. Because of the narrow interval between,the onset of fibrillations and cardiac arrest, the exact time for injection of the test compound was critical. Animals not showing definite fibrillations before death were omitted. If the treatment caused a complete restoration to normal sinus rhythm the test dose was regarded as effective and recorded in the seventh column of Table 1 . All doses (0.1-1 mg/kg) were given by rapid intravenous injection in the jugular vein, except the dose of 3 mg/kg which was administered at a rate of 1 mg/kg per min. The control group consisted of eighteen guinea-pigs, the test groups of five or ten animals.
Test for local anaesthetic effect 1. Surface anaesthetic effect
The test was carried out on male guinea-pigs weighing between 300 and 800 g by a modification of the method described by Herr (1958 
Conduction anaesthetic effect
Male mice of the NMRI strain weighing from 18-25 g were used and the method employed was essentially that described by Bianchi (1956) .
Each concentration of the test compound was tested on twenty mice.
Tests for 8-adrenergic blocking effect 1. Contraction rate, isolated guinea-pig atrium
The method was the same as described previously (Hermansen, 1968 The method used was the same as described previously (Hermansen, 1968 (2) shows the e.c.g. 45 min (a) and 62 min (b) after the start of the ouabain infusion. At (3) fibrillations occurred; at the arrows Ph QA 33 1 mg/kg (3a) and propranolol 0.5 mg/kg (3b) were given intravenously. (4) showis the e.c.g. 7 min (a) and 5 min (b) after drug administration (ordinate: 0.5 cm= 1 mV).
response relationship (column 7) giving an ED50 of 0.5 mg/kg while the maximal antifibrillatory effect of propranolol was obtained at 0.5 mg/kg. When the dose was increased to 1 mg/kg no further increase in antifibrillatory effect occurred. The ED50 was estimated to be 0.3 mg/kg while the ED50 for INPEA was 1-3 mg/kg (approximately 1.5 mg/kg). The observed effect of Ph QA 33, propranolol and INPEA on ouabain-induced cardiotoxicity could also be demonstrated by an increased tolerance to ouabain. Thus column 6 in Table 1 shows that the amount of ouabain necessary to cause cardiac arrest after fibrillations had emerged was significantly increased after drug treatment.
To ensure that the observed increase in tolerance to ouabain was not due to irrelevant factors such as different fibrillatory dose levels of the groups, the influence of this parameter on the amount of extra ouabain required to cause cardiac arrest after fibrillations had occurred, was statistically analysed. The control group (n = 18) was therefore divided into two groups, one consisting of nine guinea-pigs showing fibrillations at a dose level less than 277 ug/kg ouabain and another consisting of nine animals with a minimal fibrillatory dose above 277 jg/kg. The mean fibrillatory dose in the first group was 212 gg/kg, in the second group 342 gg/kg.
The fatal doses in the two groups were 236 and 357 pg/kg respectively. The difference between the fatal and fibrillatory dose was thus 24 + 2 and 15+3 ,ug/kg (S.E.M.) in the two groups. These two figures are significantly different (P<0.05), which means that the lower the minimal fibrillatory dose then the larger amount of extra ouabain required to cause cardiac arrest.
As a consequence of these considerations the increased tolerance to ouabain illustrated by the figures in column 6 of Table 1 can only be ascribed to drug treatment if the corresponding minimal fibrillatory dose (column 4) is not significantly lower than the control value of ouabain (277 + 18 ug/kg). This requirement was fulfilled for all the test groups and it can therefore be stated that the increases in the doses of ouabain required to cause cardiac arrest shown in column 6 of Table (2) shows the e.c.g. 40 min (a) and 48 min (b) after the start of the ouabain infusion. At (3) fibrillations occurred; at the arrows INPEA 1 mg/kg (3a) and 3 mg/kg (3b) was given intravenously. (4) shows the e.c.g. 7 min (a) and 8 min (b) after drug administration respectively (ordinate: 0.5 cm= 1 mV). Figure 3 shows the results from the surface anaesthetic test obtained with Ph QA 33, propranolol and INPEA plotted on a semi-logarithmic scale. Procaine and tetracaine were included as reference substances. As Fig. 3 shows, procaine was ineffective as a surface anaesthetic as is well known (Herr, 1958) while the ED5O for tetracaine was 2.7 mg/ml. Ph QA 33 and propranolol were equally active, the ED5Os being 7.0 and 7.5 mg/ml. respectively. INPEA was found ineffective in concentrations of 40 and 100 mg/ml. The latter finding is in accordance with previous observations (Somani & Lum, 1965; Murmann et al., 1966) The dose of ouabain which caused fibrillations and cardiac arrest is expressed as the mean±s.E.M.
The compounds were given by rapid intravenous injection immediately after fibrillations had emerged. The dose of ouabain necessary to cause cardiac arrest after fibrillations had occurred is shown in column 6. Figure 4 demonstrates the local anaesthetic effect of Ph QA 33, propranolol and INPEA after subcutaneous administration in the mouse tail. Procaine was included as a standard of reference. The figure shows clearly that propranolol is by far the most active compound with an ED5O of about 1.15 mg/ml. Ph QA 33 and procaine were found approximately equally potent (ED50: 3.1 to 3.5 mg/ml.). This corresponds to a local anaesthetic effect about one4hird of that of propranolol.
Effect of subcutaneous administration in the mouse
INPEA had a weak but significant and dose dependent local anaesthetic effect with an ED5O of about 18 mg/ml. Thus it is about 15 times weaker than propranolol and 5 times weaker than Ph QA 33. The latter finding was surprising and (1966) , who only obtained 15% anaesthesia with a 3% solution of INPEA. Fig. 4 shows that we obtained about 70% anaesthesia with the same concentration.
fl-receptor blocking effect of Ph QA 33, propranolol and INPEA 1. Effect on the adrenaline-induced increase in conitraction rate of atria in vitro Figure 5 shows that incubation of the atria in concentrations of 5 x 10-8, 1.5 x 10-8 and 1.5 x 10-6 g/ml. of Ph QA 33, propranolol and INPEA respectively caused a parallel shift of the dose-response curves to the right indicating a competitive antagonistic effect on the chronotropic action of adrenaline. Figure 5 shows that INPEA 1.5 x 10-6 g/ml. caused a smaller increase of the ED50 to adrenaline than Ph QA 33 and propranolol 5 x 10-8 and 1.5 x 10-8 respectively. The ,3-receptor blocking activity of INPEA in vitro therefore seems to be less than 1% of that of propranolol. The results also showed that propranolol was about three times more active than Ph QA 33 in this test. 2. Effect on the isoprenaline-induced fall in blood pressure in the rat Administration of INPEA 1 mg/kg intravenously caused a 13% (n=4) reduction of the isoprenaline-induced fall in blood pressure. 3 mg/kg caused a complete abolition (n= 3), indicating that the ED50 for INPEA was between 1 and 3 mg/kg. Previous experiments with Ph QA 33 and propranolol showed ED5Os of 7.5 ,g/ kg and 8 gg/kg (Hermansen 1968) indicating that the antagonistic effect of INPEA on the isoprenaline-induced blood pressure fall was less than 1% of that of Ph QA33 and propranolol. The low activity of INPEA in this test has also been demonstrated previously by Teotino, Polo Friz, Steis & Della Bella (1963) , who needed INPEA 10 mg/kg intravenously in order to obtain a complete abolition of the isoprenaline response.
Acute intravenous toxicity of Ph QA 33, propranolol and INPEA, guinea pigs Table 2 shows the lethal dose of Ph QA 33, propranolol and INPEA estimated under the same experimental conditions in which the anti-arrhythmic effect was assessed. The LD100 of INPEA is not directly comparable with that of Ph QA 33 and propranolol because the rate of injection of the latter compound was 1 mg/kg per min. At this rate it was impossible to determine the LD100 for INPEA as mentioned previously. INPEA was therefore injected at a rate of 5 mg/kg per min. The results show that INPEA is considerably less toxic,than both Ph QA 33 and propranolol. The last column in Table 2 gives the relation between anti-arrhythmic effect and intravenous LD100, indicating that the ratio between the anti-arrhythmic and toxic level of INPEA may be more favourable than that of the two other compounds. The ratio does not give any impression as to the specificity of the compounds as anti-arrhythmics because the first parameter is tested on ouabainloaded animals, the latter on unloaded ones.
Discussion
The finding that Ph QA 33 was effective against ouabain-induced arrhythmias was not surprising in view of the close pharmacological relationship to propranolol, the anti-arrhythmic properties of which are well established (Hermansen, 1968; Lucchesi, Whitsitt & Stichney, 1967) . This indicates that Ph QA 33 might also be a potential anti-arrhythmic in the clinic.
The anti-arrhythmic potency of Ph QA 33 was assessed to be about half that of -propranolol, while the surface anaesthetic action was equal to and the conduction anaesthetic action about one-third of that of propranolol. Thus the order of antiarrhythmic effect of these two compounds fits well with the general assumption that the local anaesthetic action of P-blocking agents is a crucial factor behind the antagonism of cardiac irregularities.
Particularly surprising was the observation that INPEA was capable of reversing fibrillations brought about by ouabain. INPEA has previously been reported to be effective in preventing adrenaline and methylchloroform-adrenaline-induced arrhythmias in the intact dog (Somani et Al., 1965) , in halothane-adrenaline arrhythmias in the dog heart-lung preparation (Somani et al., 1966) and against fibrillations caused by hypothermia in the cat (Nielsen & Owman, 1968) . These are all conditions involving adrenergic mechanisms.
On the contrary INPEA was found ineffective against non-catecholamine-induced arrhythmias such as cardiac rhythm disturbances induced by coronary ligation or ouabain infusions in the dog heart-lung preparation, in intact dogs (Somani et al., 1965 (Somani et al., , 1966 as well as in cats (Levitt, Ratines, Moros & Standaert, 1968) .
The latter authors were able to increase the lethal dose of ouabain by large doses of INPEA (15 mg/kg intravenously), but did not succeed in reversing ventricular tachycardia. The failure of INPEA to antagonize non-catecholamine-induced cardiac irregularities such as ouabain-arrhythmias has been explained by the reported lack of local anaesthetic effect and has actually been used in the argument for the lack of correlation between anti-arrhythmic and (3-receptor blocking properties (Somani et al., 1965 ; Murmann et al., 1966) . In accordance with our observation that INPEA does indeed reverse ouabain fibrillations, we also found the substance to possess weak but definite local anaesthetic properties when injected subcutaneously. As to the anti-arrhythmic effect of INPEA the discrepancy between previous observations and our findings may be accounted for by different choice of species and variations in the experimental method.
Although our results obtained with INPEA are incompatible with those previously published, the observations presented here confirm the proposed relationship between unspecific anti-arrhythmic and local anaesthetic action. Thus if the lack of surface anaesthetic effect of INPEA is disregarded, which may be justified by the fact that this test involves many irrelevant factors such as poor absorption from the conjunctival sac, etc., then the order of potency of the three compounds as anti-arrhythmics is the same as that as local anaesthetics, namely propranolol>Ph QA 33> INPEA (Table 1, Fig. 4) .
In order to clarify the discrepancy between previous work and the present results and to elucidate the mechanism of action of INPEA in cardiac arrhythmias further work is needed employing more elaborate methods.
With regard to the relationship between anti-arrhythmic and (-receptor blocking properties, our results support the view that the antagonistic effect of (8-blocking agents on ouabain-induced arrhythmias is independent of their affinity to (3-adrenergic receptors. Certainly the order of potency of propranolol, Ph QA 33 and INPEA is the same for the two parameters, but the low activity of INPEA as a (3-receptor blocking compound (less than 1% of propranolol) makes it unlikely that this property is responsible for its substantial anti-arrhythmic effect (intravenous ED50 -l-1.Smg/kg).
The toxicity data and the ratio between anti-arrhythmic effect and intravenous toxicity in Table 2 indicate that INPEA is considerably less toxic than Ph QA 33 and propranolol. It was not possible to obtain reversal of the fibrillations in more than 60% of the animals by the latter compound in doses of 0.5 to 1 mg/kg intravenously at which propranolol is definitely cardiodepressant in anaesthetized cats (Hermansen, 1968) . The question therefore arises as to the specificity of (3-receptor blocking agents as anti-arrhythmics. A new approach in this field has been made by the synthesis of the quaternary analogue of propranolol (ICI 46, 037) , which possesses the same anti-arrhythmic potency as propranolol without the undesirable effects associated with (3-adrenergic receptor blockade (Lucchesi & Iwami, 1968 
